Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

Compare

86 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AFX Analyst Ratings

Hold

3 Buy

7 Hold

1 Sell

Based on 11 analysts giving stock ratings to

Carl

Zeiss Meditec

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AFX Stock 12 Month Forecast

Average Price Target

€64.17

▲(6.77%Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Carl Zeiss Meditec in the last 3 months. The average price target is €64.17 with a high forecast of €86.50 and a low forecast of €41.00. The average price target represents a 6.77% change from the last price of €60.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"40":"€40","99":"€99","54.75":"€54.8","69.5":"€69.5","84.25":"€84.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€86.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":64.17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€64.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[40,54.75,69.5,84.25,99],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.1,62.13076923076923,64.16153846153847,66.1923076923077,68.22307692307692,70.25384615384615,72.28461538461539,74.31538461538462,76.34615384615384,78.37692307692308,80.40769230769232,82.43846153846154,84.46923076923076,{"y":86.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.1,60.41307692307692,60.72615384615385,61.03923076923077,61.3523076923077,61.66538461538462,61.97846153846154,62.291538461538465,62.604615384615386,62.917692307692306,63.23076923076923,63.543846153846154,63.85692307692308,{"y":64.17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,60.1,58.63076923076923,57.16153846153846,55.69230769230769,54.223076923076924,52.753846153846155,51.284615384615385,49.815384615384616,48.34615384615385,46.87692307692308,45.40769230769231,43.93846153846154,42.46923076923077,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":98.194,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.876,"date":1717200000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":65.644,"date":1719792000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":63.167,"date":1722470400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":64.257,"date":1725148800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":65.694,"date":1727740800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.776,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.429,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.103,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":58.51,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":59.501,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.1,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€86.50

Average Price Target€64.17

Lowest Price Target€41.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

€63

Hold

4.83%

Upside

Reiterated

06/06/25

Carl Zeiss Meditec's overall stock score is driven by strong financial performance and a stable balance sheet, though moderated by high valuation and bearish technical indicators. The lack of earnings call and corporate events data places more emphasis on these factors.

Sam EnglandBerenberg Bank

Berenberg Bank

€65

Hold

8.15%

Upside

Reiterated

05/29/25

Berenberg Bank Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Unknown AnalystDZ BANK AG

Not Ranked

DZ BANK AG

―

Hold

―

Reiterated

05/28/25

DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Jack Reynolds-ClarkRBC Capital

RBC Capital

€60

Hold

-0.17%

Downside

Reiterated

05/27/25

Carl Zeiss Meditec (0DHC) Gets a Hold from RBC Capital

Graham DoyleUBS

UBS

―

Hold

―

Reiterated

05/26/25

UBS Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)

Susannah LudwigBernstein

Bernstein

€71→€74

Buy

23.13%

Upside

Reiterated

05/15/25

Bernstein Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)

Richard FeltonGoldman Sachs

Goldman Sachs

€75→€77

Buy

28.12%

Upside

Reiterated

05/14/25

Goldman Sachs Remains a Buy on Carl Zeiss Meditec (0DHC)

Alexander GalitsaHauck & Aufhaeuser

Hauck & Aufhaeuser

€86.5

Buy

43.93%

Upside

Reiterated

05/14/25

Hauck & Aufhaeuser Sticks to Its Buy Rating for Carl Zeiss Meditec (0DHC)

Falko FriedrichsDeutsche Bank

Deutsche Bank

€55

Hold

-8.49%

Downside

Reiterated

05/14/25

Carl Zeiss Meditec (0DHC) Receives a Hold from Deutsche Bank

Anchal VermaJ.P. Morgan

J.P. Morgan

€41

Sell

-31.78%

Downside

Reiterated

05/13/25

J.P. Morgan Sticks to Their Sell Rating for Carl Zeiss Meditec (0DHC)

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€60

Hold

-0.17%

Downside

Reiterated

05/13/25

Hold Rating for Carl Zeiss Meditec Amid Optimistic Chinese Market Outlook and Operational Challenges

Oliver ReinbergKepler Capital

Kepler Capital

€59

Hold

-1.83%

Downside

Reiterated

04/15/25

Kepler Capital Reaffirms Their Hold Rating on Carl Zeiss Meditec (0DHC)

Sezgi OezenerHSBC

HSBC

€66→€54

Hold

-10.15%

Downside

Reiterated

12/17/24

Carl Zeiss Meditec AG (AFX:GR) (CZMWY) PT Lowered to EUR54 at HSBCHSBC analyst Sezgi Oezener lowered the price target on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) to EUR54.00 (from EUR66.00) while maintaining a Hold rating.

Unknown AnalystBaader Bank

Not Ranked

Baader Bank

€124→€97.7

Buy

62.56%

Upside

Reiterated

06/20/24

Carl Zeiss Meditec AG (AFX:GR) (CZMWY) PT Lowered to EUR97.70 at Baader HelveaBaader Helvea analyst Anas Patel lowered the price target on Carl Zeiss Meditec AG (AFX:GR) (OTC: CZMWY) to EUR97.70 (from EUR124.00) while maintaining a Buy rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

€63

Hold

4.83%

Upside

Reiterated

06/06/25

Sam EnglandBerenberg Bank

Berenberg Bank

€65

Hold

8.15%

Upside

Reiterated

05/29/25

Berenberg Bank Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Unknown AnalystDZ BANK AG

Not Ranked

DZ BANK AG

―

Hold

―

Reiterated

05/28/25

DZ BANK AG Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)

Jack Reynolds-ClarkRBC Capital

RBC Capital

€60

Hold

-0.17%

Downside

Reiterated

05/27/25

Carl Zeiss Meditec (0DHC) Gets a Hold from RBC Capital

Graham DoyleUBS

UBS

―

Hold

―

Reiterated

05/26/25

UBS Sticks to Their Hold Rating for Carl Zeiss Meditec (0DHC)

Susannah LudwigBernstein

Bernstein

€71→€74

Buy

23.13%

Upside

Reiterated

05/15/25

Bernstein Reaffirms Their Buy Rating on Carl Zeiss Meditec (0DHC)

Richard FeltonGoldman Sachs

Goldman Sachs

€75→€77

Buy

28.12%

Upside

Reiterated

05/14/25

Goldman Sachs Remains a Buy on Carl Zeiss Meditec (0DHC)

Alexander GalitsaHauck & Aufhaeuser

Hauck & Aufhaeuser

€86.5

Buy

43.93%

Upside

Reiterated

05/14/25

Hauck & Aufhaeuser Sticks to Its Buy Rating for Carl Zeiss Meditec (0DHC)

Falko FriedrichsDeutsche Bank

Deutsche Bank

€55

Hold

-8.49%

Downside

Reiterated

05/14/25

Carl Zeiss Meditec (0DHC) Receives a Hold from Deutsche Bank

Anchal VermaJ.P. Morgan

J.P. Morgan

€41

Sell

-31.78%

Downside

Reiterated

05/13/25

J.P. Morgan Sticks to Their Sell Rating for Carl Zeiss Meditec (0DHC)

Dylan Van HaaftenStifel Nicolaus

Stifel Nicolaus

€60

Hold

-0.17%

Downside

Reiterated

05/13/25

Hold Rating for Carl Zeiss Meditec Amid Optimistic Chinese Market Outlook and Operational Challenges

Oliver ReinbergKepler Capital

Kepler Capital

€59

Hold

-1.83%

Downside

Reiterated

04/15/25

Kepler Capital Reaffirms Their Hold Rating on Carl Zeiss Meditec (0DHC)

Sezgi OezenerHSBC

HSBC

€66→€54

Hold

-10.15%

Downside

Reiterated

12/17/24

Unknown AnalystBaader Bank

Not Ranked

Baader Bank

€124→€97.7

Buy

62.56%

Upside

Reiterated

06/20/24

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Carl Zeiss Meditec

1 Month

xxx

Success Rate

18/33 ratings generated profit

Average Return

+1.93%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +1.93% per trade.

3 Months

xxx

Success Rate

7/14 ratings generated profit

Average Return

+2.36%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.36% per trade.

1 Year

Anchal VermaJ.P. Morgan

Success Rate

7/14 ratings generated profit

Average Return

+8.53%

reiterated a sell rating 26 days ago

Copying Anchal Verma's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +8.53% per trade.

2 Years

xxx

Success Rate

7/14 ratings generated profit

Average Return

+7.79%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +7.79% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AFX Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AFX has received 12 Buy Ratings, 16 Hold Ratings, and 5 Sell Ratings. AFX average Analyst price target in the past 3 months is 64.17.

Each month's total comprises the sum of three months' worth of ratings.

AFX Financial Forecast

AFX Earnings Forecast

Next quarter’s earnings estimate for AFX is €0.58 with a range of €0.49 to €0.68. The previous quarter’s EPS was €0.52. AFX beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.

AFX Sales Forecast

Next quarter’s sales forecast for AFX is €559.90M with a range of €541.15M to €595.54M. The previous quarter’s sales results were €1.05B. AFX beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year AFX has Outperformed its overall industry.

AFX Stock Forecast FAQ

What is DE:AFX’s average 12-month price target, according to analysts?

Based on analyst ratings, Carl Zeiss Meditec’s 12-month average price target is 64.17.

What is DE:AFX’s upside potential, based on the analysts’ average price target?

Carl Zeiss Meditec has 6.77% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Carl Zeiss Meditec a Buy, Sell or Hold?

Carl Zeiss Meditec has a consensus rating of Hold, which is based on 3 buy ratings, 7 hold ratings and 1 sell ratings.

What is Carl Zeiss Meditec’s share price target?

The average share price target for Carl Zeiss Meditec is 64.17. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €86.50 ,and the lowest forecast is €41.00. The average share price target represents 6.77% Increase from the current price of €60.1.

What do analysts say about Carl Zeiss Meditec?

Carl Zeiss Meditec’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of Carl Zeiss Meditec?

To buy shares of DE:AFX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Carl Zeiss Meditec (AFX) Stock Forecast & Price Target

AFX Analyst Ratings

AFX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Carl Zeiss Meditec

AFX Analyst Recommendation Trends

AFX Financial Forecast

AFX Earnings Forecast

AFX Sales Forecast

AFX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts